Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Restricts Coverage For Devices More Than Drugs, Study Finds

Executive Summary

Discrepancies between FDA-approved labeling and national Medicare coverage decisions are frequent, particularly for medical devices, where CMS tends to be more restrictive than FDA, researchers reported in Health Affairs. The findings have implications for the parallel review program.

Advertisement

Related Content

FDA-CMS Parallel Review Saves Time, Clinical Trial Costs, Participant Says
CMS Policy Sets Boundaries On Transcatheter Valve Procedure
Calling All Innovators: FDA And CMS Seek Candidates For Parallel Review Pilot
FDA And CMS Agree To Share Data Routinely In Step Toward Parallel Reviews
Carotid Stenting: CREST Makes A Splash, But Market Will Depend On CMS

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT035659

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel